Complix NV

Technologiepark 94

9052 Zwijnaarde

BE

Complix NV

Foundation date

23/06/2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

Upcoming events

Latest news

  • reMYND announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease

    22 hours ago

  • Can we protect nerve cells from dying?

    22 hours ago

  • Resistance in Candida auris, how to tackle a deadly fungus

    Wednesday October 30th 2024